CA
NZ
UK
AU
IND
US
…
Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibitor developed for the treatment of acute and chronic pain. Latigo Biotherapeutics, Inc. was formerly known as WVB-Desmond, Inc. and changed its name to Latigo Biotherapeutics, Inc. in March 2019. Latigo Biotherapeutics, Inc. was incorporated in 2018 and is based in Thousand Oaks, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Latigo Biotherapeutics is a clinical-stage biopharmaceutical company developing targeted immunotherapies for oncology and related indications, advancing a pipeline through preclinical and early clinical studies. Major long-term growth drivers include positive clinical data, regulatory approvals, and strategic partnerships or licensing that could support commercialization. Investors may find exposure to innovative cancer immunotherapy platforms appealing if program milestones de-risk assets.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Type | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 |
| Income before tax | -109.17M | -61.18M |
| Net income | -109.17M | -61.18M |
| Selling general administrative | 10.86M | 6.67M |
| Reconciled depreciation | 0.25M | 0.24M |
| Operating income | -110.39M | -63.45M |
| Interest income | 2.94M | 2.26M |
| Net interest income | 2.94M | 2.26M |
| Total revenue | 0.00M | 0.00M |
| Total operating expenses | 110.39M | 63.45M |
| Total other income expense net | -1.72M | 0.00M |
| Net income from continuing ops | -109.17M | -61.18M |
| Breakdown | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Type | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 |
| Total assets | 75.52M | 22.86M |
| Total liab | 307.19M | 152.46M |
| Total stockholder equity | -231.67M | -129.60M |
| Other current liab | - | 0.25M |
| Capital stock | 0.00M | 0.00M |
| Retained earnings | -243.13M | -133.96M |
| Cash | 69.44M | 17.92M |
| Total current liabilities | 18.45M | 14.44M |
| Total current assets | 73.83M | 21.16M |
| Accounts payable | 5.01M | 7.07M |
| Non currrent assets other | 0.62M | 0.29M |
| Non current assets total | 1.69M | 1.70M |
| Capital lease obligations | 0.69M | 0.85M |
| Breakdown | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Type | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 |
| Total cash from financing activities | 149.50M | 0.61M |
| Net income | -109.17M | -61.18M |
| Change in cash | 51.80M | -50.42M |
| Begin period cash flow | 17.92M | 68.34M |
| End period cash flow | 69.72M | 17.92M |
| Total cash from operating activities | -97.56M | -50.95M |
| Issuance of capital stock | 149.38M | 0.34M |
| Depreciation | 0.25M | 0.24M |
| Capital expenditures | 0.14M | 0.07M |
| Change in working capital | 2.52M | 6.89M |
| Stock based compensation | 6.72M | 2.77M |
| Other non cash items | 0.44M | 0.33M |
| Free cash flow | -97.69M | -51.03M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
|---|---|---|---|---|---|---|
| LTGO Latigo Biotherapeutics, Inc. Common Stock |
-0.61 3.43% |
17.15 | - | - | - | - |
| NVO Novo Nordisk A/S |
0.18 0.47% |
38.80 | 41.58 | 31.15 | 2.13 | 32.99 |
| VRTX Vertex Pharmaceuticals Inc |
3.81 0.73% |
526.19 | 30.22 | 24.27 | 10.36 | 6.50 |
| REGN Regeneron Pharmaceuticals Inc |
-7.98 1.00% |
788.04 | 29.07 | 20.12 | 7.57 | 3.82 |
| ARGNF argenx SE |
- -% |
1010.26 | 45.77 | 31.25 | 13.84 | 7.12 |
Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibitor developed for the treatment of acute and chronic pain. Latigo Biotherapeutics, Inc. was formerly known as WVB-Desmond, Inc. and changed its name to Latigo Biotherapeutics, Inc. in March 2019. Latigo Biotherapeutics, Inc. was incorporated in 2018 and is based in Thousand Oaks, California.
1300 Rancho Conejo Boulevard, Thousand Oaks, CA, United States, 91320
805 716 2927
66
| Name | Title | Year Born |
|---|---|---|
| Mr. Nima Farzan M.B.A. | CEO, President & Director | 1976 |
| Ms. Neha Krishnamohan | Chief Business Officer & CFO | 1987 |
| Dr. Neil Kumar Singla M.D. | Chief Medical Officer | 1972 |
| Ms. Julia Chapman | Senior Vice President of Operations | NA |
| Ms. Caroline Dougherty | Vice President of Corporate Development | NA |
| Mr. Bryan Moyer Ph.D. | Senior Vice President of Discovery | NA |
| Ms. Polina German Pharm.D. | Senior Vice President of Clinical Pharmacology & Translational | NA |
| Ms. Sabrina Nieder | VP & Corporate Controller | NA |
| Vicki Holloway | Secretary | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.18%
Communication Services
+0.02%
Consumer Cyclical
+0.43%
Consumer Defensive
+0.03%
Energy
-0.27%
Financial Services
+0.32%
Financials
-0.23%
Healthcare
-0.17%
Industrials
+0.45%
Real Estate
-0.02%
Technology
+0.20%
Utilities
+0.20%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...